N4 Pharma PLC (N4P) Posts Earnings Results
N4 Pharma PLC (LON:N4P) announced its quarterly earnings results on Monday. The company reported GBX (2.60) (($0.04)) earnings per share (EPS) for the quarter, Bloomberg Earnings reports. The company had revenue of GBX 200 million for the quarter. N4 Pharma PLC had a net margin of 1.05% and a return on equity of 1.54%.
N4 Pharma PLC (N4P) opened at 5.62 on Monday. N4 Pharma PLC has a 52 week low of GBX 1.20 and a 52 week high of GBX 12.50. The company’s market cap is GBX 4.20 million. The stock has a 50 day moving average of GBX 5.87 and a 200 day moving average of GBX 6.78.
Separately, Beaufort Securities reiterated a “speculative buy” rating on shares of N4 Pharma PLC in a research note on Thursday, July 27th.
N4 Pharma PLC Company Profile
N4 Pharma Plc, formerly Onzima Ventures plc, is a United Kingdom-based specialist pharmaceutical company. The Company is engaged in reformulating existing drugs and vaccines to improve their performance. It operates in two divisions: generic and vaccines. Its generics division includes Sildenafil, Sartans, Aprepitant and Single dose Hepatitis B.
Receive News & Ratings for N4 Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.